JP2017502668A5 - - Google Patents

Download PDF

Info

Publication number
JP2017502668A5
JP2017502668A5 JP2016543143A JP2016543143A JP2017502668A5 JP 2017502668 A5 JP2017502668 A5 JP 2017502668A5 JP 2016543143 A JP2016543143 A JP 2016543143A JP 2016543143 A JP2016543143 A JP 2016543143A JP 2017502668 A5 JP2017502668 A5 JP 2017502668A5
Authority
JP
Japan
Prior art keywords
nucleic acid
nucleotides
length
oligonucleotide
hao1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016543143A
Other languages
English (en)
Japanese (ja)
Other versions
JP6886818B2 (ja
JP2017502668A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/072410 external-priority patent/WO2015100436A1/en
Publication of JP2017502668A publication Critical patent/JP2017502668A/ja
Publication of JP2017502668A5 publication Critical patent/JP2017502668A5/ja
Application granted granted Critical
Publication of JP6886818B2 publication Critical patent/JP6886818B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016543143A 2013-12-27 2014-12-26 二本鎖rnaによるグリコール酸オキシダーゼ(hao1)の特異的阻害に関する方法および組成物 Active JP6886818B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361921181P 2013-12-27 2013-12-27
US61/921,181 2013-12-27
US201461937838P 2014-02-10 2014-02-10
US61/937,838 2014-02-10
PCT/US2014/072410 WO2015100436A1 (en) 2013-12-27 2014-12-26 Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019202937A Division JP7109416B2 (ja) 2013-12-27 2019-11-08 二本鎖rnaによるグリコール酸オキシダーゼ(hao1)の特異的阻害に関する方法および組成物

Publications (3)

Publication Number Publication Date
JP2017502668A JP2017502668A (ja) 2017-01-26
JP2017502668A5 true JP2017502668A5 (enExample) 2018-02-08
JP6886818B2 JP6886818B2 (ja) 2021-06-16

Family

ID=53479713

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016543143A Active JP6886818B2 (ja) 2013-12-27 2014-12-26 二本鎖rnaによるグリコール酸オキシダーゼ(hao1)の特異的阻害に関する方法および組成物
JP2019202937A Active JP7109416B2 (ja) 2013-12-27 2019-11-08 二本鎖rnaによるグリコール酸オキシダーゼ(hao1)の特異的阻害に関する方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019202937A Active JP7109416B2 (ja) 2013-12-27 2019-11-08 二本鎖rnaによるグリコール酸オキシダーゼ(hao1)の特異的阻害に関する方法および組成物

Country Status (21)

Country Link
US (7) US9701966B2 (enExample)
EP (3) EP3892727A1 (enExample)
JP (2) JP6886818B2 (enExample)
AU (2) AU2014369850B2 (enExample)
CA (1) CA2935220A1 (enExample)
CY (2) CY1124203T1 (enExample)
DK (2) DK3087184T3 (enExample)
ES (2) ES2875558T3 (enExample)
FI (1) FIC20210025I1 (enExample)
FR (1) FR21C1044I2 (enExample)
HR (1) HRP20210612T1 (enExample)
HU (2) HUE055470T2 (enExample)
LT (2) LT3581654T (enExample)
LU (1) LUC00218I2 (enExample)
NO (1) NO2021038I1 (enExample)
PL (1) PL3581654T3 (enExample)
PT (1) PT3581654T (enExample)
RS (1) RS61892B1 (enExample)
SI (1) SI3581654T1 (enExample)
SM (1) SMT202100325T1 (enExample)
WO (1) WO2015100436A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
SI3581654T1 (sl) 2013-12-27 2021-08-31 Dicerna Pharmaceuticals, Inc. Postopki in sestavki za specifično inhibicijo glikolat-oksidaze (HA01) z dvoverižno RNA
JOP20200115A1 (ar) * 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EP3310918B1 (en) * 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
RU2769831C2 (ru) * 2016-10-05 2022-04-06 Зингента Партисипейшнс Аг Способы сохранения биологической активности рибонуклеиновых кислот
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
WO2019014491A1 (en) 2017-07-13 2019-01-17 Alnylam Pharmaceuticals, Inc. METHODS OF INHIBITING GENE EXPRESSION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE))
BR112021001546A2 (pt) * 2018-07-31 2021-05-04 Intellia Therapeutics, Inc. composições e métodos para a edição de gene do hidroxiácido oxidase 1 (hao1) para o tratamento da hiperoxalúria primária tipo 1 (ph1)
US20220090047A1 (en) * 2018-12-21 2022-03-24 Precision Biosciences, Inc. Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
WO2021086874A1 (en) 2019-11-01 2021-05-06 GyanRx Sciences, Inc. Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
JP2023527525A (ja) * 2020-05-22 2023-06-29 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ インターフェロン誘導オリゴヌクレオチド二重鎖および使用方法
EP4244342A1 (en) 2020-11-12 2023-09-20 Precision BioSciences, Inc. Engineered meganucleases having specificity for recognition sequences in the dystrophin gene
EP4043018A1 (en) 2021-02-10 2022-08-17 Charité - Universitätsmedizin Berlin Composition and method for reducing oxalate levels in patients receiving maintenance dialysis
EP4347833A2 (en) * 2021-06-04 2024-04-10 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting hydroxyacid oxidase 1 (hao1) and uses thereof
EP4373934A1 (en) * 2021-07-19 2024-05-29 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US513207A (en) 1894-01-23 Rail-brake
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
CA2093664C (en) 1990-10-12 2003-07-29 Fritz Eckstein Modified ribozymes
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
DK0748382T3 (da) 1993-09-02 2003-02-17 Ribozyme Pharm Inc Enzymatisk nukleinsyre indeholdende ikke-nukleotid
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
US7678897B2 (en) * 2002-02-20 2010-03-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US9879266B2 (en) * 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
ATE517992T1 (de) 2002-11-14 2011-08-15 Dharmacon Inc Funktionelle und hyperfunktionelle sirna
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
KR20070085113A (ko) 2004-05-11 2007-08-27 가부시키가이샤 알파젠 Rna간섭을 생기게 하는 폴리뉴클레오티드, 및 이를 이용한유전자발현억제 방법
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
US20090018097A1 (en) 2005-09-02 2009-01-15 Mdrna, Inc Modification of double-stranded ribonucleic acid molecules
US8178503B2 (en) * 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
JP4644619B2 (ja) 2006-03-27 2011-03-02 富士通株式会社 基地局装置、端末および帯域制御方法
DE102007021853A1 (de) 2007-05-10 2008-11-13 Norma Germany Gmbh Steckkupplung und Stutzen für eine Steckkupplung
US20110288147A1 (en) 2008-09-22 2011-11-24 Bob Dale Brown Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop
CN101752443B (zh) 2008-12-08 2012-06-20 鸿富锦精密工业(深圳)有限公司 光伏电池
AU2009336191B2 (en) 2008-12-18 2017-08-24 Novo Nordisk A/S Extended dicer substrate agents and methods for the specific inhibition of gene expression
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
EP2756845B1 (en) 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
CN102803955B (zh) 2009-05-21 2015-10-21 系统生物学研究所 肝损伤的新标志物
PT3301177T (pt) 2011-11-18 2020-06-29 Alnylam Pharmaceuticals Inc Agentes de arni, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
US9133461B2 (en) * 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
SI3581654T1 (sl) 2013-12-27 2021-08-31 Dicerna Pharmaceuticals, Inc. Postopki in sestavki za specifično inhibicijo glikolat-oksidaze (HA01) z dvoverižno RNA
JOP20200115A1 (ar) * 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))

Similar Documents

Publication Publication Date Title
JP2017502668A5 (enExample)
JP2016528887A5 (enExample)
JP2015133993A5 (enExample)
JP2016526529A5 (enExample)
IL262667A (en) Nucleosides, nucleotides and modified nucleic acids, and their uses
IL264555B (en) Specific primers for nucleic acid amplification
JP2010524500A5 (enExample)
WO2015196128A3 (en) Alternative nucleic acid molecules and uses thereof
EP2791160A4 (en) NUCLEOSIDE, NUCLEOTIDE, AND MODIFIED NUCLEIC ACID COMPOSITIONS
LT3041854T (lt) Nukleorūgščių specifinės vietos žymėjimo fermentais in vitro būdas, įvedant nenatūralius nukleotidus
SI3294325T1 (sl) Krepitev učinka car-izdelanih t celic s cepljenjem z nukleinsko kislino
MX2016007541A (es) Moléculas modificadas de ácido nucleico y usos de las mismas.
DK4108671T3 (da) Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
PT3118311T (pt) Ácido nucleico anti-sentido
HUE043054T2 (hu) Szubsztituált nukleozidok, nukleotidok és ezek analógjai
JP2013005803A5 (enExample)
EP3237613A4 (en) Visualizing modified nucleotides and nucleic acid interactions in single cells
PT3632202T (pt) Locais genéticos associados a fertilidade acrescida em milho
DK3294756T3 (da) Retroviral partikel, omfattende mindst to forskellige indkapslede, ikke-virale RNA'er
WO2016106387A3 (en) Nucleic acid aptamers to treat histone-induced disease states
EP3418289A4 (en) ARTIFICIAL NUCLEOSIDE AND ARTIFICIAL NUCLEOTIDE AND ARTIFICIAL OLIGONUCLEOTIDE
JP2016108250A5 (enExample)
RU2015154352A (ru) Генетическая конструкция для экспрессии генов в клетках насекомого polypedilum vanderplanki
JP2012024594A5 (ja) 払拭具及び払拭方法
EP3677268A4 (en) UNIT POLYIONIC COMPLEX FILLED WITH NUCLEIC ACID